Taken together, this study demonstrated that metformin synergized with PD-L1 MAb increased the infiltration capacity of CD8+ T cells, enhanced tumor immune response, and had better efficacy in the treatment of NSCLC than metformin or PD-L1 MAb. The gene discussed is CD8A; the disease is neoplasm.